Lanreotide
Who holds supplier records for Lanreotide? 2 organisations hold a current record for Lanreotide: an active US FDA Type II Drug Master File. A further 1 organisation has only historical (inactive) DMF filings. Recorded organisation countries for current records: Spain (1) and India (1).
Most records are filed under another form of this substance: Lanreotide Acetate (10 current sources). A DMF or CEP is listed under the form it names.
Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records
Cite as: PharmaTek, “Lanreotide: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/lanreotide
Reading the evidence
- 2 current records
Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.
- 1 with a company-level GMP certificate on record
These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.
Current records (2)
Organisations holding an active US FDA Type II Drug Master File or a CEP for Lanreotide. Country is the organisation's recorded country, not necessarily the manufacturing site.
- BCN PEPTIDES SASpainActive DMF 39254 · latest filing Dec 2023
- Piramal Pharma LimitedIndia Company GMP cert on recordActive DMF 42310 · latest filing Jul 2025
The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.
Historical records (1)
Organisations whose Type II DMFs for Lanreotide are no longer active. These show a past filing, not current supply.
Show all 1 historical record
- IPSEN MANUFACTURING IRELAND LIMITEDIreland · Inactive DMF 8974 · filed Feb 1991
US product patents and exclusivity
The FDA Orange Book lists patents and exclusivities for specific approved products (4 listed products contain Lanreotide). The latest listed exclusivity runs to 20 Mar 2027. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.
Other forms of this substance
A DMF or CEP is listed under the form it names. Salts, esters and hydrates of the same active substance have their own records:
Overview
Lanreotide is a protein active pharmaceutical ingredient (ChEMBL CHEMBL1201185).
Chemical identity
- IUPAC name
- (4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2R)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
- Canonical SMILES
- C[C@H]([C@@H](C(=O)N)NC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)N)O
- InChIKey
- PUDHBTGHUJUUFI-SCTWWAJVSA-N
- Synonyms
- Angiopeptin, Lanreotida, Lanreotide, Somatuline autogel, Somatuline la, Ipstyl, Lanreotidum, Lanreotide Autogel, BIM 23014, Bim-23014, DC 13-116, Somatulina
Record history
No change to the current records between 13 Nov 2026 and 16 Nov 2026.
Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week
What these records establish
- An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
- A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
- Historical records show a past filing, not current supply.
- Company GMP certificates are matched to the organisation, not to the site making this substance.
- A substance missing from these registers is not evidence that no supplier exists.
Frequently asked questions
Which organisations hold current supplier records for Lanreotide?
2 organisations hold an active US FDA Type II Drug Master File or a CEP for Lanreotide: BCN PEPTIDES SA (Spain) and Piramal Pharma Limited (India). A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.
Which Lanreotide Drug Master Files are active?
BCN PEPTIDES SA (DMF 39254) and Piramal Pharma Limited (DMF 42310). The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.
What do the historical Lanreotide records mean?
1 organisation has only inactive Type II DMFs for Lanreotide. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.
How do I qualify a Lanreotide supplier?
Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.
Do you supply Lanreotide?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.